Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H12Cl2N2O |
| Molecular Weight | 271.142 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CC1=NC2=C(O)C(Cl)=CC(Cl)=C2C=C1
InChI
InChIKey=YZPOQCQXOSEMAZ-UHFFFAOYSA-N
InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
747408-78-2
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
DTXSID701029571
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
10016012
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
DB05565
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
SUB196791
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
100000182617
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | |||
|
PBT2
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY | PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease.Clinical trials: PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals, and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia. The drug also missed efficacy goals for Huntington's disease. | ||
|
Q7K6GJQ4O4
Created by
admin on Sat Dec 16 11:32:32 UTC 2023 , Edited by admin on Sat Dec 16 11:32:32 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
